Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8498279 | 0.84 | MMP1 (0.62) | MMP2POLBALDH1A1MMP1MMP3 | |
| SCHEMBL8144145 | 0.84 | MMP1 (0.62) | MMP2POLBALDH1A1MMP1MMP3 | |
| SCHEMBL8106846 | 0.83 | KMT2A (0.64) | ANPEPMMP2POLBKMT2AALDH1A1 | |
| SCHEMBL21551113 | 0.83 | KMT2A (0.64) | ANPEPMMP2POLBKMT2AALDH1A1 | |
| SCHEMBL2227030 | 0.83 | KMT2A (0.64) | ANPEPMMP2POLBKMT2AALDH1A1 | |
| SCHEMBL5409165 | 0.82 | MME (0.49) | ANPEPMMP2HCRTR1HCRTR2POLB | |
| SCHEMBL7166230 | 0.82 | MME (0.49) | ANPEPMMP2HCRTR1HCRTR2POLB | |
| SCHEMBL6980507 | 0.82 | MME (0.49) | ANPEPMMP2HCRTR1HCRTR2POLB | |
| SCHEMBL1980805 | 0.82 | HCRTR1 (0.47) | ANPEPMMP2HCRTR1HCRTR2KMT2A | |
| SCHEMBL9505317 | 0.81 | MMP2 (0.61) | ANPEPMMP2POLBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326834-B1 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | H LEE MOFFITT CANCER CT & RES (US) | 2011-06-29 | — | — | EP | disclosed |
| US-6809093-B2 | DRUG RESISTANCE THERAPY | H. LEE MOFFITT CANCER & RESEARCH INSTITUTE, INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1326834-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | The Procter & Gamble Company (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032868-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | ABCC1, SLC11A2, ABCB1 | ANPEP 745/4885MMP2 1167/4885HCRTR1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.